Jefferies Group's LAB Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 17,675 shares of Standard BioTools Inc. (LAB) worth $14,541, representing 0.00% of the portfolio. First purchased in 2023-Q3, this short-term holding has been held for 5 quarters.
Based on 13F filings, Jefferies Group has maintained this position in LAB for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2024, adding 63,000 shares. Largest reduction occurred in Q2 2024, reducing 119,400 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Standard BioTools (LAB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Standard BioTools (LAB) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +17,675 | New Buy | 17,675 | $0.82 |
| Q2 2024 | -119,400 | Sold Out | 0 | $0.00 |
| Q1 2024 | +63,000 | Add 111.70% | 119,400 | $2.71 |
| Q3 2023 | +56,400 | New Buy | 56,400 | $2.90 |
Jefferies Group's Standard BioTools Investment FAQs
Jefferies Group first purchased Standard BioTools Inc. (LAB) in Q3 2023, acquiring 56,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Standard BioTools Inc. (LAB) for 5 quarters since Q3 2023.
Jefferies Group's largest addition to Standard BioTools Inc. (LAB) was in Q1 2024, adding 119,400 shares worth $323,574.
According to the latest 13F filing for Q2 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 17,675 shares of Standard BioTools Inc. (LAB), valued at approximately $14,541.
As of the Q2 2026 filing, Standard BioTools Inc. (LAB) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Standard BioTools Inc. (LAB) was 119,400 shares, as reported at the end of Q1 2024.